Givosiran (Givlarri)

Covered for the FDA‑approved treatment of adults (≥18) with acute hepatic porphyria; pediatric (<18) and off‑label uses are excluded. Approval requires documented clinical AHP features plus elevated urinary ALA or PBG, a porphyria attack in the past 6 months requiring hospitalization/urgent visit or IV hemin, and prescription by or in consultation with a gastroenterologist, hepatologist, or AHP specialist (with supporting documentation).

"Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP)."

Sign up to see full coverage criteria, indications, and limitations.